DK1060247T3 - Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons - Google Patents

Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons

Info

Publication number
DK1060247T3
DK1060247T3 DK99909562T DK99909562T DK1060247T3 DK 1060247 T3 DK1060247 T3 DK 1060247T3 DK 99909562 T DK99909562 T DK 99909562T DK 99909562 T DK99909562 T DK 99909562T DK 1060247 T3 DK1060247 T3 DK 1060247T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
methods
immune response
composition containing
binding agent
Prior art date
Application number
DK99909562T
Other languages
Danish (da)
English (en)
Inventor
Andrew D Weinberg
Original Assignee
Sisters Of Providence In Orego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21845027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1060247(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sisters Of Providence In Orego filed Critical Sisters Of Providence In Orego
Application granted granted Critical
Publication of DK1060247T3 publication Critical patent/DK1060247T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK99909562T 1998-02-24 1999-02-23 Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons DK1060247T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2871698A 1998-02-24 1998-02-24
PCT/US1999/003908 WO1999042585A1 (fr) 1998-02-24 1999-02-23 Compositions renfermant un agent de liaison du recepteur ox-40 ou un acide nucleique codant pour ledit recepteur 0x-40 et techniques favorisant une reponse immunitaire specifique a un antigene

Publications (1)

Publication Number Publication Date
DK1060247T3 true DK1060247T3 (da) 2009-01-26

Family

ID=21845027

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99909562T DK1060247T3 (da) 1998-02-24 1999-02-23 Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons

Country Status (12)

Country Link
EP (2) EP1997893A1 (fr)
JP (1) JP4741074B2 (fr)
AP (1) AP1261A (fr)
AT (1) ATE408011T1 (fr)
AU (1) AU2873999A (fr)
CA (1) CA2321161C (fr)
CY (1) CY1108597T1 (fr)
DE (1) DE69939526D1 (fr)
DK (1) DK1060247T3 (fr)
ES (1) ES2315008T5 (fr)
PT (1) PT1060247E (fr)
WO (1) WO1999042585A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60317677T2 (de) * 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
EP1633372B1 (fr) * 2003-06-13 2011-11-30 The Trustees of The University of Pennsylvania Vaccins, agents immunotherapeutiques et leurs methodes d'utilisation
WO2007123737A2 (fr) 2006-03-30 2007-11-01 University Of California Procédés et compositions de sécrétion localisée d'anticorps anti-ctla-4
AU2014202213B2 (en) * 2007-12-14 2016-05-12 Bristol-Myers Squibb Company Binding Molecules to the Human OX40 Receptor
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
CA2809089C (fr) 2010-08-23 2018-12-18 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procedes d'utilisation
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP3508215A3 (fr) 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Amélioration de l'activité anticancéreuse de protéines de fusion fc immunomodulatrices
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
EP2964638B1 (fr) 2013-03-06 2017-08-09 Astrazeneca AB Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
CA2935878C (fr) 2014-03-12 2023-05-02 Curevac Ag Combinaison de vaccination et d'agonistes de ox40
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
DK3303396T5 (da) 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
WO2017046746A1 (fr) 2015-09-15 2017-03-23 Acerta Pharma B.V. Associations thérapeuthiques d'un inhibiteur de la btk et d'une molécule de liaison à gitr, d'un agoniste de 4-1bb, ou d'un agoniste d'ox40
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
CA2955184A1 (fr) 2016-01-25 2017-07-25 Pfizer Inc. Combinaison d'un agoniste ox40 et d'un agoniste 4-1bb destinee au traitement du cancer
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
WO2018027204A1 (fr) 2016-08-05 2018-02-08 Genentech, Inc. Anticorps multivalents et multiépitopiques ayant une activité agoniste et procédés d'utilisation
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
BR112019012328A2 (pt) 2016-12-15 2019-11-19 Abbvie Biotherapeutics Inc anticorpos anti-ox40 e seus usos
MX2019007963A (es) 2017-01-06 2019-10-21 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
US11142579B2 (en) 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40
CA3090795A1 (fr) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du recepteur a2a de l'adenosine et combinaisons therapeutiques de til et d'antagonistes du recepteur a2 a de l'adenosine
EP3768715A1 (fr) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Anticorps contre mica et/ou micb et leurs utilisations
JP7384896B2 (ja) * 2018-07-22 2023-11-21 ヘルス リサーチ インコーポレイテッド 主要組織適合遺伝子複合（ｍｈｃ）クラスｉｉ－発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CA3141452A1 (fr) 2019-05-24 2020-12-03 Pfizer Inc. Polytherapies a l'aide d'inhibiteurs cdk
WO2020239558A1 (fr) 2019-05-24 2020-12-03 Pfizer Inc. Polythérapies faisant appel à des inhibiteurs de cdk
WO2020243570A1 (fr) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Signature de localisation cellulaire et polythérapie
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022055399A1 (fr) * 2020-09-10 2022-03-17 Михаил Иванович Воевода Procédé de traitement d'infections à l'aide d'agonistes/bloqueurs de récepteur ox40
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
WO2022130206A1 (fr) 2020-12-16 2022-06-23 Pfizer Inc. POLYTHÉRAPIES À INHIBITEURS DE TGFβR1
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
EP4314068A1 (fr) 2021-04-02 2024-02-07 The Regents Of The University Of California Anticorps dirigés contre un cdcp1 clivé et leurs utilisations
WO2023178329A1 (fr) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Procédés d'isolement de polypeptides
KR20250022071A (ko) 2022-06-02 2025-02-14 브리스톨-마이어스 스큅 컴퍼니 항체 조성물 및 이의 이용 방법
EP4583999A1 (fr) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Procédés de séparation d'agent chélateur
WO2024196952A1 (fr) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Évaluation de sous-type de tumeur pour une thérapie anticancéreuse
WO2025038763A1 (fr) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Procédé de chromatographie en flux continu d'hydroxyapatite céramique
WO2025145207A1 (fr) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Polythérapie d'inhibiteur de kras et d'agent de déplétion des treg

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4902288A (en) 1985-12-03 1990-02-20 Marylou Ingram Implantable immunotherapy system using stimulated cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0302894B1 (fr) 1986-04-28 1992-11-19 Endotronics Inc. Procede de culture de leucocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5665362A (en) 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
US5837261A (en) 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
EP0733373A3 (fr) 1995-03-23 1999-04-28 Bristol-Myers Squibb Company Compositions et procédés pour augmenter l'immunogénicité des cellules tumorales par l'administration de cellules transformées pour l'expression de B7 et CD2 protéines

Also Published As

Publication number Publication date
JP2002504334A (ja) 2002-02-12
CA2321161A1 (fr) 1999-08-26
EP1060247A1 (fr) 2000-12-20
JP4741074B2 (ja) 2011-08-03
EP1060247B1 (fr) 2008-09-10
WO1999042585A9 (fr) 1999-11-04
EP1997893A1 (fr) 2008-12-03
ATE408011T1 (de) 2008-09-15
CA2321161C (fr) 2011-12-20
EP1060247B2 (fr) 2011-10-26
CY1108597T1 (el) 2014-04-09
ES2315008T3 (es) 2009-03-16
WO1999042585A1 (fr) 1999-08-26
ES2315008T5 (es) 2012-03-06
DE69939526D1 (de) 2008-10-23
AP1261A (en) 2004-03-19
AU2873999A (en) 1999-09-06
PT1060247E (pt) 2008-12-22
AP2000001903A0 (en) 2000-09-30

Similar Documents

Publication Publication Date Title
DK1060247T3 (da) Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
DK1066049T3 (da) Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse
NO20000084D0 (no) Fenolisk harpiks for limblanding, fremstilling derav og limpreparat inneholdende harpiksen
IL200404A0 (en) 191P4D12(b) PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME; ANTIBODIES BINDING THERETO AND USES THEREOF
ZA983148B (en) Modified TNFÓ, DNA encoding such modified TNFÓ and vacines comprising said TNFÓ and DNA.
DK1147068T3 (da) Fast sammensætning, der indeholder faste partikler og bindemiddel
DE69841745D1 (de) Aufzeichnungsgerät, Aufzeichnungsverfahren, Aufzeichnungsmedium
DE69014678D1 (de) Verbesserte Haftung in gehärtetem Zustand aufweisende, härtbare Organopolysiloxanzusammensetzung.
ID21109A (id) Pesawat perekam dan atau pereproduksi piringan, dan pesawat pengisi piringan
DK1003383T4 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
EP1117436A4 (fr) Polypeptide neisseria spp, sequence d'acide nucleique et utilisations correspondantes
DK1015433T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oler, fremgangsmåder til fremstilling af disse og deres anvendelse som lægemidler
DK1009817T3 (da) RTD-receptor
NO995348D0 (no) Glideskjötsammenstilling, og fremgangsmåte for bruk av denne
NO20022969D0 (no) Sammensetninger og metoder for L-nukleosider, L-nukleotider og analoger derav
DE69727741D1 (de) Niedrigviskose Polyisocyanate hergestellt aus monomeren Triisocyanaten
NO995062D0 (no) <Beta>-anyloidpeptid-bindende proteiner og polynuldeotider som kodes for samme
DE59712488D1 (de) Einrichtung zur Reduktion der Datenrate
NO20015376D0 (no) Peptider fra TT-virus-sekvensen og monospesifikke antistoffer som binder til TT-viruset
AU2002302070A1 (en) Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
EE9900566A (xx) Helicobacter pylori FlgE pol�peptiidi sisaldavad vaktsiinikoostised
DE69817234D1 (de) Flüssige, härtbare Harzzusammensetzung
ZA97360B (en) DB, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof.
ZA992262B (en) Vectors for transferring nucleic acids, compositions containing them and their uses.